Skip to main content
Vir Biotechnology, Inc. logo

Vir Biotechnology, Inc. — Investor Relations & Filings

Ticker · VIR ISIN · US92764N1028 US Manufacturing
Open in API
Filings indexed 727 across all filing types
Latest filing 2021-07-06 Director's Dealing
Country US United States of America
Listing US VIR

About Vir Biotechnology, Inc.

https://www.vir.bio/

Vir Biotechnology, Inc. is a clinical-stage immunology company that leverages the immune system to treat and prevent serious infectious diseases and other conditions. The company's pipeline is built on two primary technology platforms: a next-generation antibody platform for identifying and optimizing therapeutic candidates, and the PRO-XTEN® protease-releasable masking technology for applications in oncology. Vir's main therapeutic area is infectious diseases, featuring a leading program for chronic hepatitis delta, and is complemented by strategic programs in oncology. The company has demonstrated its capabilities by developing antibody-based medicines for significant health challenges, including COVID-19 and Ebola.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2021-07-06 English
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2021-07-06 English
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2021-07-06 English
FORM 4 SUBMISSION
Director's Dealing
2021-07-01 English
FORM 4 SUBMISSION
Director's Dealing
2021-06-29 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events or updates by a public company. The content includes detailed clinical trial results, updates on drug development programs, regulatory progress, and presentations of clinical data. It is not a full annual or quarterly financial report, nor is it an earnings release or management discussion. The document is lengthy (15,000 characters) and contains substantive information about ongoing clinical trials and regulatory updates, which are typical for a current report (8-K). The document does not fit into categories like M&A, director dealings, or dividend notices. It is not a report publication announcement since it contains detailed data and analysis, not just a notice of report availability. Therefore, the best classification is Regulatory Filings (RNS), as 8-K filings are general regulatory announcements that do not fit other specific categories.
2021-06-28 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.